Home/Filings/4/0001209191-18-013642
4//SEC Filing

Chari Ravi S. 4

Accession 0001209191-18-013642

CIK 0000860730other

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 7:30 PM ET

Size

21.3 KB

Accession

0001209191-18-013642

Insider Transaction Report

Form 4
Period: 2018-02-22
Chari Ravi S.
SVP-Clinical Excellence
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2018-02-25930930 total
    Exp: 2026-02-25Common Stock (930 underlying)
  • Award

    Common Stock

    2018-02-22+8,8009,151 total
  • Award

    Common Stock

    2018-02-22+3009,451 total
  • Tax Payment

    Common Stock

    2018-02-22$100.54/sh3,151$316,8026,300 total
  • Exercise/Conversion

    Common Stock

    2018-02-25+9307,230 total
  • Tax Payment

    Common Stock

    2018-02-25$100.84/sh227$22,8917,003 total
  • Award

    Stock Appreciation Right

    2018-02-22+1,0501,050 total
    Exercise: $47.97From: 2018-02-22Exp: 2024-02-05Common Stock (1,050 underlying)
Footnotes (5)
  • [F1]On February 4, 2015, the reporting person was granted 4,400 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2015-2017. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2015-2017 earnings per share, the number of performance share units that vested equaled two times the units granted.
  • [F2]On February 5, 2014, the reporting person was granted 2,000 restricted stock units. The restricted stock units were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the restricted stock units subject to such criteria vested, resulting in the vesting of 300 restricted stock units.
  • [F3]Restricted stock units convert into common stock on a one-for-one basis.
  • [F4]On February 5, 2014, the reporting person was granted 7,000 stock appreciation rights. The stock appreciation rights were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 1,050 stock appreciation rights.
  • [F5]On February 25, 2016, the reporting person was granted 1,860 restricted stock units, vesting in two equal annual installments beginning on the second anniversary of the grant date.

Issuer

HCA Healthcare, Inc.

CIK 0000860730

Entity typeother

Related Parties

1
  • filerCIK 0001632795

Filing Metadata

Form type
4
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 7:30 PM ET
Size
21.3 KB